Helen Tremlett

Assistant Professor
Department of Medicine, Division of Neurology

Phone: 604 822-0759

Web pages:
Directory listing



  • PhD, Welsh School of Pharmacy, University of Wales, 1996
  • BPharm, School of Pharmacy and Pharmacology, Bath University, 1991


  • Multiple sclerosis

Research Interests

  • Pharmacoepidemiology, epidemiology, multiple sclerosis
  • Side-effects of the immunomodulatory drugs for multiple sclerosis
  • Natural history of multiple sclerosis: disease progression and relapses
  • Prognosis and predictors of disease progression in multiple sclerosis

Selected Publications

Tremlett H, Paty D, Devonshire V The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923. 

Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology. 2006;66:172-177. 

Tremlett H, Devonshire V. Does the season or month of birth influence disease progression in multiple sclerosis? Neuroepidemiology 2006;26:195-198 

Tremlett H, Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-959 

Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J. Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology 2006;67:1291-1293 

Sayao AL, Devonshire V, Tremlett H. Longitudinal Follow-up of Benign MS at 20 years. Neurology. 2007 Feb 13;68(7):496-500. 

Tremlett H, Oger J Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis 2008; 14:94-105 

Tremlett H, Zhao Y, Devonshire V. The natural history of secondary-progressive multiple sclerosis Multiple Sclerosis 2008. 14: 314–324 

Forwell S, Brunham S, Tremlett H, Morrison W, Tentzerakis S, Bogle N, Oger J. Primary and non-primary fatigue in multiple sclerosis. International Journal of MS Care. 2008; 10:14-20 

Koch M, De Keyser J, Tremlett H Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis 2008; 14:793-798. 

Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 2008 17(6):565-76. 

Tremlett H, Zhao Y, Joseph J, Devonshire V and the UBC MS Clinic Neurologists. Relapses in multiple sclerosis are age and time-dependent. J Neurol Neurosurg Psychiatry 2008;79;1368-1374 

Tremlett H, van der Mei I, Pittas F, Blizzard L, Paley G, Mesaros G, Woodbaker R, Nunez M, Dwyer T, Taylor B, Ponsonby AL. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008; 31: 271-279 

Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology. 2009 Mar;256(3):374-81 

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y and the UBC Neurologists. The impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73 1616-1623 


Honours and Awards:

  • Multiple Sclerosis Society of Canada, Don Paty Career Development Award

  • Michael Smith Foundation for Health Research, Scholar Award

  • UBC Faculty of Medicine Merit and Performance Award

  • Jacqueline Du Pre Grant from the Multiple Sclerosis International Federation's (MSIF) Scientific Programmes Committee (International Medical & Scientific Board)